Lupin’s consolidated net profit jumped 77% to Rs 801 crore for Q1 ending June 30, 2024, up from Rs 452 crore a year earlier. Revenue increased to Rs 5,600 crore from Rs 4,814 crore. Growth was driven by new products and improved margins. North America sales reached Rs 2,041 crore, a 28% increase, while India sales rose to Rs 1,926 crore. The strong performance highlights Lupin’s effective growth strategy and operational efficiencies. This robust profit growth indicates solid prospects for the company and the pharmaceutical sector.
